🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsOral GLP-1 AgonistsRybelsus real-world vs clinical trial efficacy — need advice

Rybelsus real-world vs clinical trial efficacy — need advice

julia.endo Sun, Feb 8, 2026 at 12:40 PM 9 replies 967 viewsPage 1 of 2
julia.endo
Senior Member
1,890
9,012
Feb 2024
Cincinnati, OH
Feb 8, 2026 at 12:40 PM#1

On 25mg oral, four months in, and my results are closer to the low-dose injectable arm than to the numbers being quoted for 50mg.

The practical numbers: about 1% oral bioavailability, 30 minutes fasted before food, no more than 120ml of plain water, and coffee counts as food for this purpose.

The bit I cannot resolve on my own is how much of the oral variability is the SNAC absorption window and how much is dose, because the two get conflated constantly.

Practical detail welcome, however dull — the duller the better.

17 12anna.melb_AU, mark_tokyo, hans_munich and 14 others
Reply Quote Save Share Report
Dr.ObesityLA
VIP Member
3,567
19,876
Dec 2023
Los Angeles, CA
Feb 8, 2026 at 12:45 PM#2

Short answer first, then the reasoning. Orforglipron is the more interesting oral story because it is not a peptide at all. Being a small molecule it does not need SNAC, does not need the fasting window, and has oral bioavailability in the tens of percent rather than about one.

16 11KarenAZ_mom, zoe_NC, Dr.ObesityLA and 13 others
Reply Quote Save Share Report
LeilaHI
Member
167
789
Jan 2025
Honolulu, HI
Feb 8, 2026 at 12:50 PM#3
Dr.ObesityLA said:
Orforglipron is the more interesting oral story because it is not a peptide at all.

That is correct as far as it goes, and here is where it stops going. The absorption variability is real, but it partly averages out over weeks — the steady-state trough is less erratic than any single day would suggest. Where it bites is in the first fortnight, when people conclude the tablet does nothing.

15 10mike_nyc, VendorMark, COA_Karl and 12 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
MikeNYC_runner
Member
378
1,678
Jul 2024
New York, NY
Feb 8, 2026 at 12:55 PM#4
julia.endo said:
On 25mg oral, four months in, and my results are closer to the low-dose injectable arm than to the numbers being quoted for 50mg.

Can confirm the pattern julia.endo describes. The OASIS programme put 50mg oral in the same territory as 2.4mg injectable — around 15% mean weight loss — but it needed a dose 20 times larger to get there because almost none of the tablet is absorbed. The dose numbers are not comparable across routes and quoting them side by side confuses people.

14 9GenomicsKate, Dr.ObesityMed, HealthEcon_DC and 11 others
Reply Quote Save Share Report
Dr.LipidDallas
VIP Member
2,678
14,567
Dec 2023
Dallas, TX
Feb 8, 2026 at 1:20 PM#5

Adding the clinical framing, because it changes how the question reads. The useful move here is to separate what is established from what is widely repeated. Those two sets overlap less than the confident tone of most write-ups suggests, and the second set is where nearly all the disagreement on this board comes from.

13 8Dr.PulmRoch, maya_sedona, stefan_berlin and 10 others
Reply Quote Save Share Report

Similar Threads

Orforglipron Phase 3 ATTAIN-1 topline — oral non-peptide GLP-116 replies
Oral semaglutide 50mg (Rybelsus HD) — OASIS program results12 replies
Danuglipron BID dosing — Pfizer oral GLP-1 update7 replies
Oral vs injectable GLP-1: bioavailability and efficacy comparison5 replies
Orforglipron food interaction profile — no fasting requirement15 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register